Last updated on June 2019

Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A


Brief description of study

Open label, single arm, multicenter phase II trial.

Detailed Study Description

Preemptive therapy with Venetoclax for high risk stage A Chronic Lymphoid Leukemia patients, a phase II trial of the FILO group.

PREVENE (PREemptive VENEtoclax) trial.

Clinical Study Identifier: NCT03766763

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.